The Effect of Neutropenia and Filgrastim (G-CSF) on Cancer Patients With Coronavirus Disease 2019 (COVID-19) Infection. (10th June 2021)

• Record Type: Journal Article
• Authors: Zhang, Allen W; Morjaria, Sejal; Kaltsas, Anna; Hohl, Tobias M; Parameswaran, Rekha; Patel, Dhruvkumar; Zhou, Wei; Predmore, Jacqueline; Perez-Johnston, Rocio; Jee, Justin; Daniyan, Anthony F; Perales, Miguel-Angel; Taur, Ying
• Is Part Of: Clinical infectious diseases. Volume 74:Number 4(2022)
• Page Start: 567
• Page End: 574
• Publication Date: 2021-06-10
• Subjects: COVID-19 -- granulocyte colony stimulating factor -- cancer -- neutropenia; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciab534
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Neutropenia is commonly encountered in cancer patients. Recombinant human granulocyte colony-stimulating factor (G-CSF, filgrastim), a cytokine that initiates proliferation and differentiation of mature granulocytes, is widely given to oncology patients to counteract neutropenia, reducing susceptibility to infection. However, the clinical impact of neutropenia and G-CSF use in cancer patients with coronavirus disease 2019 (COVID-19) remains unknown. Methods: An observational cohort of 379 actively treated cancer patients with COVID-19 was assembled to investigate links between concurrent neutropenia and G-CSF administration on COVID-19-associated respiratory failure and death. These factors were encoded as time-dependent predictors in an extended Cox model, controlling for age and underlying cancer diagnosis. To determine whether the degree of granulocyte response to G-CSF affected outcomes, the degree of response to G-CSF, based on rise in absolute neutrophil count (ANC) 24 hours after growth factor administration, was also incorporated into a similar Cox model. Results: In the setting of active COVID-19 infection, outpatient receipt of G-CSF led to an increased number of hospitalizations (hazard ratio [HR]: 3.54, 95% confidence interval [CI]: 1.25–10.0, P value: .017). Furthermore, among inpatients, G-CSF administration was associated with increased need for high levels of oxygen supplementation and death (HR: 3.56, 95% CI: 1.19–10.2, P value: .024). This effect was predominantly seen in patients that exhibited a high response to G-CSF based on their ANC increase post-G-CSF administration (HR: 7.78, 95% CI: 2.05–27.9, P value: .004). Conclusions: The potential risks versus benefits of G-CSF administration should be considered in neutropenic cancer patients with COVID-19, because G-CSF administration may lead to worsening clinical and respiratory status. Abstract : The safety profile of G-CSF in patients with severe SARS-CoV2 infection is unclear. Here, we systematically characterized the effect G-CSF on the risk for respiratory decompensation and death in cancer patients who were infected with COVID-19.